Recent News

• 06.02.2026 - Myriad Genetics Names Raj Jampa as New Chief Technology Officer
• 05.27.2026 - Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting
• 05.26.2026 - Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
• 05.15.2026 - Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
• 05.07.2026 - Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
• 05.05.2026 - Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business
• 04.30.2026 - Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan
• 04.28.2026 - Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026
• 04.16.2026 - Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026
• 04.14.2026 - Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan

Recent Filings

• 06.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.02.2026 - 3 Initial statement of beneficial ownership of securities
• 05.14.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.12.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.05.2026 - EX-99.1 EX-99.1
• 05.05.2026 - 8-K Current report
• 05.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 04.15.2026 - 4 Statement of changes in beneficial ownership of securities
• 04.15.2026 - 4 Statement of changes in beneficial ownership of securities